COVID19 OutcomeS in Myeloma and the Impact of VaCcines

Completed

Conditions studied: Multiple Myeloma

In brief

The COVID-19 pandemic has had an outsized impact on individuals with underlying social and medical vulnerability, leading to increased rates of severe disease, hospitalization, and death in these groups. Participants with underlying immune compromise, such as those with multiple myeloma, represent one such group. The advent of vaccines against SARS-CoV-2 has significantly limited morbidity and mortality across all groups, but the effectiveness of vaccination in individuals who are less likely to mount sufficient antibody response is uncertain. For this reason, booster vaccines have been recommended for those with underlying immune compromise. However, several key gaps remain in our understanding of how to best protect these individuals. There is a dearth of real-world evidence about the effectiveness of vaccination and boosters in patients who are immunocompromised, and very little information specifically about the recently approved mRNA boosters. Additionally, rates of vaccination and booster uptake in the United States remain low. A rapid, decentralized method of ascertaining information related to booster vaccine response and adverse events related to vaccines and COVID-19 infection is critical not only to answer questions about the booster vaccines, but to develop an infrastructure for answering similar questions about future vaccines or other diseases.

Key facts

Study ID

NCT05831787

Run by

ASH Research Collaborative

People needed

201

Starts

2024-01-23

Expected to finish

2024-12-31

Last updated by the study team

2026-05-18

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of multiple myeloma per the International Myeloma Working Group and currently receiving active treatment for any phase of the disease, including initial therapy, maintenance, or relapsed disease.
• Access to the internet
• An active patient portal (or willingness to activate)
• Willing to electronically sign the study-specific informed consent and authorization form

You may not qualify if…

• Non-English speaking
• Lack of internet access
• Cognitive impairment precluding ability to provide informed consent

Where it is running

• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• UNC-Chapel Hill — Chapel Hill, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.